Forkhead box O1 transcription factor; a therapeutic target for diabetic cardiomyopathy.

IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-08-14 eCollection Date: 2024-01-01 DOI:10.3389/jpps.2024.13193
Tanin Shafaati, Keshav Gopal
{"title":"Forkhead box O1 transcription factor; a therapeutic target for diabetic cardiomyopathy.","authors":"Tanin Shafaati, Keshav Gopal","doi":"10.3389/jpps.2024.13193","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiovascular disease including diabetic cardiomyopathy (DbCM) represents the leading cause of death in people with diabetes. DbCM is defined as ventricular dysfunction in the absence of underlying vascular diseases and/or hypertension. The known molecular mediators of DbCM are multifactorial, including but not limited to insulin resistance, altered energy metabolism, lipotoxicity, endothelial dysfunction, oxidative stress, apoptosis, and autophagy. FoxO1, a prominent member of forkhead box O transcription factors, is involved in regulating various cellular processes in different tissues. Altered FoxO1 expression and activity have been associated with cardiovascular diseases in diabetic subjects. Herein we provide an overview of the role of FoxO1 in various molecular mediators related to DbCM, such as altered energy metabolism, lipotoxicity, oxidative stress, and cell death. Furthermore, we provide valuable insights into its therapeutic potential by targeting these perturbations to alleviate cardiomyopathy in settings of type 1 and type 2 diabetes.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"13193"},"PeriodicalIF":2.9000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11349536/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy and Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/jpps.2024.13193","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Cardiovascular disease including diabetic cardiomyopathy (DbCM) represents the leading cause of death in people with diabetes. DbCM is defined as ventricular dysfunction in the absence of underlying vascular diseases and/or hypertension. The known molecular mediators of DbCM are multifactorial, including but not limited to insulin resistance, altered energy metabolism, lipotoxicity, endothelial dysfunction, oxidative stress, apoptosis, and autophagy. FoxO1, a prominent member of forkhead box O transcription factors, is involved in regulating various cellular processes in different tissues. Altered FoxO1 expression and activity have been associated with cardiovascular diseases in diabetic subjects. Herein we provide an overview of the role of FoxO1 in various molecular mediators related to DbCM, such as altered energy metabolism, lipotoxicity, oxidative stress, and cell death. Furthermore, we provide valuable insights into its therapeutic potential by targeting these perturbations to alleviate cardiomyopathy in settings of type 1 and type 2 diabetes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
叉头盒 O1 转录因子;糖尿病心肌病的治疗靶点。
包括糖尿病心肌病(DbCM)在内的心血管疾病是导致糖尿病患者死亡的主要原因。糖尿病心肌病是指在没有潜在血管疾病和/或高血压的情况下出现心室功能障碍。DbCM 的已知分子介质是多因素的,包括但不限于胰岛素抵抗、能量代谢改变、脂肪毒性、内皮功能障碍、氧化应激、细胞凋亡和自噬。FoxO1 是叉头盒 O 转录因子的重要成员,参与调节不同组织中的各种细胞过程。FoxO1 表达和活性的改变与糖尿病患者的心血管疾病有关。在此,我们概述了 FoxO1 在与 DbCM 相关的各种分子介质中的作用,如能量代谢改变、脂肪毒性、氧化应激和细胞死亡。此外,我们还对 FoxO1 的治疗潜力提出了有价值的见解,即通过靶向这些扰动来缓解 1 型和 2 型糖尿病患者的心肌病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.90
自引率
0.00%
发文量
29
审稿时长
6-12 weeks
期刊介绍: The Journal of Pharmacy and Pharmaceutical Sciences (JPPS) is the official journal of the Canadian Society for Pharmaceutical Sciences. JPPS is a broad-spectrum, peer-reviewed, international pharmaceutical journal circulated electronically via the World Wide Web. Subscription to JPPS is free of charge. Articles will appear individually as soon as they are accepted and are ready for circulation.
期刊最新文献
Development of a dry powder formulation for pulmonary delivery of azithromycin-loaded nanoparticles. Expanding the eligibility criteria for drugs in Canada's time-limited health technology assessment and temporary drug access processes will further accelerate access to new medicines. Targeting ketone body metabolism to treat fatty liver disease. Pharmacometabolomics of sulfonylureas in patients with type 2 diabetes: a cross-sectional study. Evaluation of the rational prescription of linezolid, the prevalence of thrombocytopenia and major drug interactions in patients with cardiovascular diseases: are there any cautions?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1